Core Insights - Helius Medical Technologies' shares dropped 16% following the announcement of its first Solana treasury acquisition, which involved purchasing 760,190 SOL at an average price of $231, valuing the treasury at approximately $168 million [1] - The company has raised $500 million through an oversubscribed private placement to initiate its treasury operations, indicating strong support from stakeholders in the Solana ecosystem [2] - Despite the initial surge in share price, Helius' stock has seen fluctuations, currently trading at $20.19, which is still a 218% increase over the past month [3] Group 1 - Helius Medical Technologies acquired 760,190 SOL at an average price of $231, valuing its treasury at around $168 million [1] - The company maintains approximately $335 million in cash, which will facilitate further acquisitions for its Solana treasury [1] - The firm announced its intention to build a Solana treasury last week, raising $500 million via a private placement led by Pantera Capital and Summer Capital [2] Group 2 - Helius' shares initially surged by 141% to $18.27 but have since fallen to $20.19, despite being up 218% over the last month [3] - The strategy of accumulating SOL at a lower cost basis while retaining capital for opportunistic purchases reflects the company's focus on maximizing shareholder value [4] - Solana's price has dropped around 6.9% in the last 24 hours, trading at $221.19, which is below Helius' average purchase price [4]